Literature DB >> 23205722

Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.

Kelly E Dunn1, Anthony Defulio, Jeffrey J Everly, Wendy D Donlin, Will M Aklin, Paul A Nuzzo, Jeannie-Marie S Leoutsakos, Annie Umbricht, Michael Fingerhood, George E Bigelow, Kenneth Silverman.   

Abstract

Oral naltrexone has high potential for use as a relapse prevention pharmacotherapy for opiate dependence yet suffers from notoriously poor adherence. This study evaluated whether entry to a therapeutic workplace could reinforce adherence with oral naltrexone. Opiate-dependent and cocaine-using injection drug users were detoxified, inducted onto oral naltrexone, and randomly assigned to a contingency (n = 35) or prescription (n = 32) group for a 26-week period. Contingency participants were required to ingest naltrexone under staff observation to gain access to the therapeutic workplace. Prescription participants received a take-home supply of naltrexone and could access the workplace independent of naltrexone ingestion. Primary outcome measures were percent of urine samples positive for naltrexone at 30-day assessments and negative for opiates and cocaine at 30-day assessments. Contingency participants provided significantly more urine samples that were positive for naltrexone compared with prescription participants (72% vs. 21%, p < .01); however, no effect of experimental group was observed on percent opiate-negative (71% vs. 60%, p = .19.) or cocaine-negative (56% vs. 53%, p = .82) samples in the contingency and prescription groups, respectively. Opiate-positive samples were significantly more likely to occur in conjunction with cocaine (p < .001) and when not protected by naltrexone (p < .02), independent of experimental group. Overall, these results show that contingent access to a therapeutic workplace significantly promoted adherence to oral naltrexone, and that the majority of opiate use occurred in conjunction with cocaine use, suggesting that untreated cocaine use may limit the effectiveness of oral naltrexone in promoting opiate abstinence. (c) 2013 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23205722      PMCID: PMC3641088          DOI: 10.1037/a0030743

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  43 in total

1.  Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.

Authors:  S L Walsh; J T Sullivan; K L Preston; J E Garner; G E Bigelow
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

2.  Properties of the urn randomization in clinical trials.

Authors:  L J Wei; J M Lachin
Journal:  Control Clin Trials       Date:  1988-12

3.  Models for longitudinal data: a generalized estimating equation approach.

Authors:  S L Zeger; K Y Liang; P S Albert
Journal:  Biometrics       Date:  1988-12       Impact factor: 2.571

4.  New data from the Addiction Severity Index. Reliability and validity in three centers.

Authors:  A T McLellan; L Luborsky; J Cacciola; J Griffith; F Evans; H L Barr; C P O'Brien
Journal:  J Nerv Ment Dis       Date:  1985-07       Impact factor: 2.254

5.  The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures.

Authors:  L N Robins; J Wing; H U Wittchen; J E Helzer; T F Babor; J Burke; A Farmer; A Jablenski; R Pickens; D A Regier
Journal:  Arch Gen Psychiatry       Date:  1988-12

6.  Operant analysis of human heroin self-administration and the effects of naltrexone.

Authors:  N K Mello; J H Mendelson; J C Kuehnle; M S Sellers
Journal:  J Pharmacol Exp Ther       Date:  1981-01       Impact factor: 4.030

7.  Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN.

Authors:  W M Compton; L B Cottler; K B Dorsey; E L Spitznagel; D E Mager
Journal:  Drug Alcohol Depend       Date:  1996-07       Impact factor: 4.492

Review 8.  Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.

Authors: 
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

9.  Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts.

Authors:  L San; G Pomarol; J M Peri; J M Olle; J Cami
Journal:  Br J Addict       Date:  1991-08

10.  Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors.

Authors:  H A Navaline; E C Snider; C J Petro; D Tobin; D Metzger; A I Alterman; G E Woody
Journal:  AIDS Res Hum Retroviruses       Date:  1994       Impact factor: 2.205

View more
  25 in total

Review 1.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

Review 2.  William L. Woolverton: a case history in unraveling the behavioral pharmacology of stimulants.

Authors:  Michael A Nader; Robert L Balster; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2014-05-20       Impact factor: 5.250

3.  Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

Authors:  Brantley P Jarvis; August F Holtyn; Meredith S Berry; Shrinidhi Subramaniam; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  J Subst Abuse Treat       Date:  2017-04-20

4.  Academic skills of chronically unemployed drug-addicted adults.

Authors:  August F Holtyn; Anthony DeFulio; Kenneth Silverman
Journal:  J Vocat Rehabil       Date:  2015

Review 5.  Behavior analysts in the war on poverty: Developing an operant antipoverty program.

Authors:  Kenneth Silverman; August F Holtyn; Shrinidhi Subramaniam
Journal:  Exp Clin Psychopharmacol       Date:  2018-09-27       Impact factor: 3.157

6.  The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial.

Authors:  August F Holtyn; Mikhail N Koffarnus; Anthony DeFulio; Sigurdur O Sigurdsson; Eric C Strain; Robert P Schwartz; Jeannie-Marie S Leoutsakos; Kenneth Silverman
Journal:  Prev Med       Date:  2014-03-04       Impact factor: 4.018

7.  When Added to Opioid Agonist Treatment, Psychosocial Interventions do not Further Reduce the Use of Illicit Opioids: A Comment on Dugosh et al.

Authors:  Robert P Schwartz
Journal:  J Addict Med       Date:  2016 Jul-Aug       Impact factor: 3.702

8.  The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.

Authors:  Brantley P Jarvis; August F Holtyn; Anthony DeFulio; Mikhail N Koffarnus; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2019-02-14       Impact factor: 4.492

Review 9.  Opioid use disorder.

Authors:  John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh
Journal:  Nat Rev Dis Primers       Date:  2020-01-09       Impact factor: 52.329

10.  Reduction of classroom noise levels using group contingencies.

Authors:  Brandon M Ring; Sigurdur O Sigurdsson; Sean L Eubanks; Kenneth Silverman
Journal:  J Appl Behav Anal       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.